MedTrace Logo

Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)

NCT01397799 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2015-12-07

No results posted yet for this study

Summary

This Phase 1b study will determine the maximum tolerated dose of KX2-391 given as a once-daily dose, in elderly patients with acute myelogenous leukemia.

Conditions

  • Acute Myelogenous Leukemia

Interventions

DRUG

KX2-391

Oral dose solution, once-daily dosing for 28-days. Subjects may continue beyond the first 28-days until disease progression or unacceptable toxicity develops.

Sponsors & Collaborators

  • Kinex Pharmaceuticals Inc.

    lead INDUSTRY

Principal Investigators

  • James Thompson, MD · Roswell Park Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01397799 on ClinicalTrials.gov